Holds one active US DMF and one valid CEP for ethinylestradiol, filing since 2007. Its 2022 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Holds one active US DMF and one valid CEP for ethinylestradiol, filing since 2007. Its 2022 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Holds 3 valid CEPs for ethinylestradiol, filing since 2019. Its GMP is recognised in 28 markets.
Holds one active US DMF for ethinylestradiol, filing since 1972. Its 2023 FDA inspection closed as VAI, and its GMP is recognised in 46 markets.
Holds 2 valid CEPs for ethinylestradiol, filing since 2019. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 30 markets.
Holds one valid CEP for ethinylestradiol, filing since 2017. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 22 markets.
Its 2022 FDA inspection closed as VAI.
Holds one valid CEP for ethinylestradiol, filing since 2026. Its 2017 FDA inspection closed as NAI.
Its 2024 FDA inspection closed as VAI.
Registered with DAV (Vietnam) for ethinylestradiol. Its GMP is recognised in 1 market.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
Contract manufacturers make to order rather than holding their own filing for this molecule.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free